HIV and AIDS Trial, Recruiting NCT06784908 Sponsor: Yale University Condition: HIV and AIDS
Back to Hiv Aids

HIV and AIDS Trial, Recruiting

NCT06784908
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are in good general health, confirmed through a screening check-up
  • People who can read English, complete study assessments, and agree in writing and verbally to take part

People living with HIV (all HIV-positive groups):

  • People who have tested positive for HIV-1
  • People whose HIV is currently undetectable in their blood
  • People who take their HIV medications consistently and as directed

People living with HIV who also use cannabis (PLWH + cannabis use group):

  • People whose urine test shows recent cannabis use
  • People who meet the clinical criteria for both cannabis use disorder and major depressive disorder, as assessed using a structured diagnostic interview (confirm with trial site)

Healthy comparison group (HIV-negative, no cannabis use):

  • People who have tested negative for HIV-1
  • People whose urine test shows no drug use
  • People with no major physical or mental health diagnoses

HIV-positive only group (no cannabis use):

  • People who have tested positive for HIV-1
  • People whose urine test shows no drug use
  • People with no major physical or mental health diagnoses

Cannabis use only group (HIV-negative):

  • People who have tested negative for HIV-1
  • People whose urine test shows recent cannabis use
  • People who meet the clinical criteria for both cannabis use disorder and major depressive disorder, as assessed using a structured diagnostic interview (confirm with trial site)

Who may not be able to join:

  • People who currently meet the criteria for a moderate or severe substance use disorder involving cocaine, alcohol, opioids, sedatives, or nicotine
  • People with a current or past history of cocaine or opioid use disorder
  • People with a history of any psychotic disorder
  • People currently diagnosed with bipolar disorder or post-traumatic stress disorder (PTSD)
  • People who are currently experiencing psychosis, suicidal thoughts, homicidal thoughts, or a manic episode
  • People with significant underlying health conditions affecting the brain, kidneys, thyroid, or heart that could interfere with participation
  • People currently taking medications known to affect stress hormone systems or immune function in the brain (confirm with trial site)
  • People who are pregnant, breastfeeding, or using hormonal contraception that affects the body's cortisol stress response

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rajita Sinha, Ph.D., Yale University

Phone: 203-737-4791

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
16 January 2025
Est. completion
31 January 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in cortisol levels; Change in adrenocorticotropic hormone (ACTH) levels; Change in pain stress

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov